
    
      The study will include 10 children (age: 3-15 years old). Patients will receive low doses of
      Interleukin 2 (0.5 million UI/mÂ²/ injection, subcutaneously).

      The treatment will be initiated with an induction phase of one injection per day for 5
      consecutive days, followed by a maintenance phase in which patients will receive one
      injection every 14 days for 6 months.
    
  